HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
BIOBOARD - AUSTRALIA
Senz Oncology initiates VAL-1000 clinical trial in patients with acute leukemias
Senz Oncology Pty Ltd (Senz) has announced that the first patient has commenced treatment in a Phase I/II clinical evaluation of VAL-1000 in patients with acute leukemias (protocol SO-2012-1). 

The single-arm, open-label clinical trial will be conducted under the guidance of Principal Investigator, Dr. Andrew Wei, Head of Leukemia Services at The Alfred Hospital, Melbourne, Australia.

“We are very pleased to have Dr. Wei as Principal Investigator for the VAL-1000 Phase I/II clinical trial,” said Dr. Ian Nisbet, Executive Director, Senz Oncology. “Dr. Wei's input into the preclinical studies provided new scientific insights and the clinical rationale for VAL-1000 in acute leukaemias”.

The primary objective of the trial is to evaluate the safety and tolerability of VAL-1000 in adult patients with acute leukemias that are unsuitable for treatment with standard chemotherapy treatments. 

The trial will also evaluate secondary objectives including assessing patient related efficacy outcomes, measuring VAL-1000 pharmacokinetics and defining a dose level for testing in subsequent Phase II clinical trials. 

Approximately 900 patients are diagnosed with Acute Myeloid Leukemia (AML) in Australia annually. The majority will relapse, especially those over the age of 60 and with poor risk cytogenetic and molecular characteristics. Patients falling into these categories have very limited treatment options once standard approaches have been exhausted.

According to Dr. Anthony Filippis, Executive Director, Senz Oncology, “The trial will be the first time that VAL-1000 has been tested clinically for the treatment of acute leukaemias; if ultimately shown to be safe and efficacious it could provide a completely new treatment option for patients.”

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
news Wheat Genome Sequencing Gets Major Boost
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy